![Comparison of Dose Adjustment Strategies for Obesity in High-dose Cyclophosphamide Among Adult Hematopoietic Cell Transplantation Recipients: Pharmacokinetic Analysis - Transplantation and Cellular Therapy, Official Publication of the American Society ... Comparison of Dose Adjustment Strategies for Obesity in High-dose Cyclophosphamide Among Adult Hematopoietic Cell Transplantation Recipients: Pharmacokinetic Analysis - Transplantation and Cellular Therapy, Official Publication of the American Society ...](https://www.astctjournal.org/cms/attachment/698908d4-81ac-4adb-b145-4a5070f2c653/ga1_lrg.jpg)
Comparison of Dose Adjustment Strategies for Obesity in High-dose Cyclophosphamide Among Adult Hematopoietic Cell Transplantation Recipients: Pharmacokinetic Analysis - Transplantation and Cellular Therapy, Official Publication of the American Society ...
![Formulation Options for Cyclophosphamide : February 2022 : Oncology Safety - Pharmacy Purchasing & Products Magazine Formulation Options for Cyclophosphamide : February 2022 : Oncology Safety - Pharmacy Purchasing & Products Magazine](https://www.pppmag.com/files/article-images/ppp_2202_onc_patientsafety_figure.jpg)
Formulation Options for Cyclophosphamide : February 2022 : Oncology Safety - Pharmacy Purchasing & Products Magazine
![These highlights do not include all the information needed to use CYCLOPHOSPHAMIDE INJECTION safely and effectively. See full prescribing information for CYCLOPHOSPHAMIDE INJECTION. CYCLOPHOSPHAMIDE injection, for intravenous use Initial U.S. Approval ... These highlights do not include all the information needed to use CYCLOPHOSPHAMIDE INJECTION safely and effectively. See full prescribing information for CYCLOPHOSPHAMIDE INJECTION. CYCLOPHOSPHAMIDE injection, for intravenous use Initial U.S. Approval ...](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=cyclophosphamide-fig2.jpg&id=584243)
These highlights do not include all the information needed to use CYCLOPHOSPHAMIDE INJECTION safely and effectively. See full prescribing information for CYCLOPHOSPHAMIDE INJECTION. CYCLOPHOSPHAMIDE injection, for intravenous use Initial U.S. Approval ...
![These highlights do not include all the information needed to use CYCLOPHOSPHAMIDE CAPSULES safely and effectively. See full prescribing information for CYCLOPHOSPHAMIDE CAPSULES CYCLOPHOSPHAMIDE capsules, for oral use Initial U.S. Approval:1959 These highlights do not include all the information needed to use CYCLOPHOSPHAMIDE CAPSULES safely and effectively. See full prescribing information for CYCLOPHOSPHAMIDE CAPSULES CYCLOPHOSPHAMIDE capsules, for oral use Initial U.S. Approval:1959](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=f57dbebf-f145-4e3c-bfef-b7907f6e01eb-02.jpg&id=554031)
These highlights do not include all the information needed to use CYCLOPHOSPHAMIDE CAPSULES safely and effectively. See full prescribing information for CYCLOPHOSPHAMIDE CAPSULES CYCLOPHOSPHAMIDE capsules, for oral use Initial U.S. Approval:1959
![Reduced post-transplant cyclophosphamide doses in haploidentical hematopoietic cell transplantation for elderly patients with hematological malignancies | Bone Marrow Transplantation Reduced post-transplant cyclophosphamide doses in haploidentical hematopoietic cell transplantation for elderly patients with hematological malignancies | Bone Marrow Transplantation](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41409-022-01908-y/MediaObjects/41409_2022_1908_Fig1_HTML.png)
Reduced post-transplant cyclophosphamide doses in haploidentical hematopoietic cell transplantation for elderly patients with hematological malignancies | Bone Marrow Transplantation
![The effect of granulocyte-colony stimulating factor, decitabine, and busulfan–cyclophosphamide versus busulfan–cyclophosphamide conditioning on relapse in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia evolving from ... The effect of granulocyte-colony stimulating factor, decitabine, and busulfan–cyclophosphamide versus busulfan–cyclophosphamide conditioning on relapse in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia evolving from ...](https://www.thelancet.com/cms/attachment/36095ed8-7b85-4a20-8bc4-3ac4fa70ecad/gr1_lrg.jpg)
The effect of granulocyte-colony stimulating factor, decitabine, and busulfan–cyclophosphamide versus busulfan–cyclophosphamide conditioning on relapse in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia evolving from ...
![Dosing of mesna to avoid urothelial toxicity from cyclophosphamide infusion - Journal of Prescribing Practice Dosing of mesna to avoid urothelial toxicity from cyclophosphamide infusion - Journal of Prescribing Practice](https://www.prescribingpractice.com/media/bp5fx5du/calculation_16_1000x667.jpg)
Dosing of mesna to avoid urothelial toxicity from cyclophosphamide infusion - Journal of Prescribing Practice
![Pharmaceuticals | Free Full-Text | Pharmacokinetics and Pharmacogenetics of Cyclophosphamide in a Neonate and Infant Childhood Cancer Patient Population Pharmaceuticals | Free Full-Text | Pharmacokinetics and Pharmacogenetics of Cyclophosphamide in a Neonate and Infant Childhood Cancer Patient Population](https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-14-00272/article_deploy/html/images/pharmaceuticals-14-00272-g003.png?1616232849)
Pharmaceuticals | Free Full-Text | Pharmacokinetics and Pharmacogenetics of Cyclophosphamide in a Neonate and Infant Childhood Cancer Patient Population
![These highlights do not include all the information needed to use CYCLOPHOSPHAMIDE safely and effectively. See full prescribing information for CYCLOPHOSPHAMIDE. CYCLOPHOSPHAMIDE injection, for intravenous use Initial U.S. Approval: 1959 These highlights do not include all the information needed to use CYCLOPHOSPHAMIDE safely and effectively. See full prescribing information for CYCLOPHOSPHAMIDE. CYCLOPHOSPHAMIDE injection, for intravenous use Initial U.S. Approval: 1959](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=cyclophosphamide-for-injection-usp-2.jpg&id=606181)
These highlights do not include all the information needed to use CYCLOPHOSPHAMIDE safely and effectively. See full prescribing information for CYCLOPHOSPHAMIDE. CYCLOPHOSPHAMIDE injection, for intravenous use Initial U.S. Approval: 1959
![Immunological Effects of Low-dose Cyclophosphamide in Cancer Patients Treated With Oncolytic Adenovirus: Molecular Therapy Immunological Effects of Low-dose Cyclophosphamide in Cancer Patients Treated With Oncolytic Adenovirus: Molecular Therapy](https://www.cell.com/cms/attachment/cd22f0c8-1524-4c03-b666-7a80d91c712d/gr1_lrg.jpg)
Immunological Effects of Low-dose Cyclophosphamide in Cancer Patients Treated With Oncolytic Adenovirus: Molecular Therapy
![Comparison of Dose Adjustment Strategies for Obesity in High-dose Cyclophosphamide Among Adult Hematopoietic Cell Transplantation Recipients: Pharmacokinetic Analysis - Transplantation and Cellular Therapy, Official Publication of the American Society ... Comparison of Dose Adjustment Strategies for Obesity in High-dose Cyclophosphamide Among Adult Hematopoietic Cell Transplantation Recipients: Pharmacokinetic Analysis - Transplantation and Cellular Therapy, Official Publication of the American Society ...](https://www.astctjournal.org/cms/asset/9128c19c-393e-4e3e-90aa-ce3b3f824fc5/ga1.jpg)
Comparison of Dose Adjustment Strategies for Obesity in High-dose Cyclophosphamide Among Adult Hematopoietic Cell Transplantation Recipients: Pharmacokinetic Analysis - Transplantation and Cellular Therapy, Official Publication of the American Society ...
![IJMS | Free Full-Text | Low Dose Cyclophosphamide Modulates Tumor Microenvironment by TGF-β Signaling Pathway IJMS | Free Full-Text | Low Dose Cyclophosphamide Modulates Tumor Microenvironment by TGF-β Signaling Pathway](https://www.mdpi.com/ijms/ijms-21-00957/article_deploy/html/images/ijms-21-00957-g003.png)
IJMS | Free Full-Text | Low Dose Cyclophosphamide Modulates Tumor Microenvironment by TGF-β Signaling Pathway
![Pazopanib and Oral Cyclophosphamide in Women With Platinum-Resistant or -Refractory Epithelial Ovarian Cancer | JCO Global Oncology Pazopanib and Oral Cyclophosphamide in Women With Platinum-Resistant or -Refractory Epithelial Ovarian Cancer | JCO Global Oncology](https://ascopubs.org/na101/home/literatum/publisher/asco/journals/content/go/2020/go.2020.6/jgo.19.00331/20200328/images/large/jgo.19.00331t3.jpeg)